Pulmatrix secures EU patent for dry powder delivery tech

By Gareth Macdonald

- Last updated on GMT

iStock/Avesun
iStock/Avesun

Related tags Dry powder inhalers Small molecule drugs Intellectual property Us food and drug administration

Pulmatrix Inc has extended its IP portfolio with a European patent for its particle-based drug delivery technology.

The patent – EP 2410981 B1 – covers the Pulmatrix’s powder technology – known as iSperse – which is used formulate small molecule drugs for inhaled delivery. The firm already has patents protecting the technology in the US - 9,433,576 - and Japan.

Particles produced using the iSperse platform can be delivered using commercially available passive dry powder inhalers in either capsule or blister-based formats. Another advantage – according to Pulmatrix – is that formulations can be produced more cheaply.

CEO Robert Clarke said: “It gives us a strong intellectual property protection position in Europe as we move forward with our drug candidates in COPD, fungal infections and other diseases​.”

Manufacturing

Pulmatrix’s drug candidates – of which a Ph II COPD drug called PUR0200 is the most advanced – is made by US Capsule and delivery technology firm Capsugel, which signed an exclusive manufacturing deal in 2016​.

Under that agreement Capsugel makes Pulmatrix’s drugs for clinical trials using spray-drying capacity at the Oregon manufacturing facility it acquired when it bought Bend Research in 2013​.  

According to a financial statement released this month, Pulmatrix plans continue chemistry manufacturing and controls (CMC) development work on PUR0200 in the first half of 2016 in preparation for a planned bioequivalence study.

The firm also said it will ask the US Food and Drug Administration (FDA) approval for a pre-IND meeting in the second half of the year.

In addition, Pulmatrix said it aims to secure a development partner for PUR0200 this year.

Related news

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Product Brochure

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us

Products

View more

Webinars